Dianthus Therapeutics (NASDAQ:DNTH) Stock: Insider Ryan Savitz Sells 100,713 Shares

Posted by Brian Himes on Nov 14th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) EVP Ryan Savitz sold 100,713 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $90.54, for a total value of $9,118,555.02. Following the completion of the transaction, the executive vice president owned 29,276 shares of the company’s stock, valued at approximately $2,650,649.04. The trade was a 77.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ryan Savitz also recently made the following trade(s):

On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.56, for a total transaction of $1,605,085.44.
On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Stock Down 0.7%

Shares of DNTH opened at $91.81 on Friday. The business’s 50 day moving average price is $88.45 and its 200-day moving average price is $86.56. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88. The stock has a market cap of $5.17 billion, a P/E ratio of -23.01 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The company had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently made changes to their positions in the company. EFG International AG purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at approximately $49,000. GAMMA Investing LLC raised its position in Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after purchasing an additional 254 shares in the last quarter. Fifth Third Bancorp grew its stake in shares of Dianthus Therapeutics by 23.6% during the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after purchasing an additional 129 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Dianthus Therapeutics in the second quarter valued at $93,000. Finally, Nisa Investment Advisors LLC raised its position in Dianthus Therapeutics by 75.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock valued at $93,000 after purchasing an additional 453 shares during the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Dianthus Therapeutics

Here are a few of the latest headlines about DNTH:

Positive Sentiment: Analyst coverage is broadly favorable. A report highlights bullish views on DNTH, and HC Wainwright reiterated a Buy rating with a $158 price target and a bullish FY2026 earnings outlook. The available FY2026 report does not detail the estimate or its rationale. Article: Analysts Are Bullish on These Healthcare Stocks Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
Negative Sentiment: EVP Ryan Savitz sold 124,042 shares from November 9–12 for about $11.2 million, sharply reducing his reported stake. The filings do not state why he sold, but the scale of the transactions may concern investors. Article: Dianthus Therapeutics EVP Sells Shares

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $158.00 price target on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Raymond James Financial restated a “strong-buy” rating and set a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday, November 5th. Wedbush boosted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Roth Capital started coverage on Dianthus Therapeutics in a research report on Tuesday, October 27th. They set a “buy” rating and a $113.00 target price for the company. Finally, Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $128.77.

Check Out Our Latest Stock Analysis on DNTH

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.